Efficacy of the new double-layer stent for unresectable distal malignant biliary obstruction: a single-center retrospective study.

Diagnostic and Therapeutic Endoscopy Pub Date : 2012-01-01 Epub Date: 2012-03-07 DOI:10.1155/2012/680963
Ken Ito, Yoshinori Igarashi, Takahiko Mimura, Yui Kishimoto, Yoshinori Kikuchi, Naoki Okano
{"title":"Efficacy of the new double-layer stent for unresectable distal malignant biliary obstruction: a single-center retrospective study.","authors":"Ken Ito, Yoshinori Igarashi, Takahiko Mimura, Yui Kishimoto, Yoshinori Kikuchi, Naoki Okano","doi":"10.1155/2012/680963","DOIUrl":null,"url":null,"abstract":"<p><p>Background and Aims. For distal malignant biliary obstruction in cases with short life expectancy, occlusion of plastic stents (PSs) does not usually occur before death, and the application of such a procedure is considered adequate from the viewpoint of cost-effectiveness. Methods and Setting. A new commercially available DLS with side holes, a conventional DLS, and, uncovered self-expanding metal stents (SEMSs) were retrospectively evaluated in patients with jaundice due to unresectable distal malignant biliary obstruction. Results. A total of 64 patients received endoscopic biliary stenting (23 patients with the new DLS, 24 patients with conventional DLS, and 17 patients with uncovered SEMS) from December 2002 to August 2009. Median patency time was found to be 198 days for the new DLS group and 99 days for the conventional DLS group, revealing a significant difference between devices. There was, however, no significant difference in median patency time between the new DLS and the uncovered SEMS (198 days versus 344 days). Conclusion. The new DLS is efficient and safe and may be considered the first choice for unresectable distal malignant obstruction in cases with short life expectancy.</p>","PeriodicalId":11288,"journal":{"name":"Diagnostic and Therapeutic Endoscopy","volume":"2012 ","pages":"680963"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic and Therapeutic Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2012/680963","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/3/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Aims. For distal malignant biliary obstruction in cases with short life expectancy, occlusion of plastic stents (PSs) does not usually occur before death, and the application of such a procedure is considered adequate from the viewpoint of cost-effectiveness. Methods and Setting. A new commercially available DLS with side holes, a conventional DLS, and, uncovered self-expanding metal stents (SEMSs) were retrospectively evaluated in patients with jaundice due to unresectable distal malignant biliary obstruction. Results. A total of 64 patients received endoscopic biliary stenting (23 patients with the new DLS, 24 patients with conventional DLS, and 17 patients with uncovered SEMS) from December 2002 to August 2009. Median patency time was found to be 198 days for the new DLS group and 99 days for the conventional DLS group, revealing a significant difference between devices. There was, however, no significant difference in median patency time between the new DLS and the uncovered SEMS (198 days versus 344 days). Conclusion. The new DLS is efficient and safe and may be considered the first choice for unresectable distal malignant obstruction in cases with short life expectancy.

Abstract Image

Abstract Image

Abstract Image

新型双层支架治疗无法切除的远端恶性胆道梗阻的疗效:一项单中心回顾性研究。
背景和目的。对于预期寿命较短的远端恶性胆道梗阻病例,塑料支架(PSs)的闭塞通常不会在死亡前发生,从成本效益的角度来看,应用这种手术被认为是适当的。方法与环境。对因无法切除的远端恶性胆道梗阻而导致黄疸的患者进行了回顾性评估,评估对象包括一种新的带侧孔的商用 DLS、一种传统 DLS 和无盖自膨胀金属支架(SEMS)。结果2002年12月至2009年8月期间,共有64名患者接受了内镜胆道支架治疗(23名患者使用新型DLS,24名患者使用传统DLS,17名患者使用无盖SEMS)。结果发现,新型 DLS 组和传统 DLS 组的中位通畅时间分别为 198 天和 99 天,两种设备之间存在显著差异。不过,新型 DLS 和无盖 SEMS 的中位通畅时间(198 天对 344 天)没有明显差异。结论。新型 DLS 高效、安全,可作为预期寿命较短病例中不可切除远端恶性阻塞的首选。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信